Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) – It’s Official: Obesity Is a Disease

According to the American Medical Association, obesity is now officially a disease.

A highly preventable disease, but a disease nonetheless.

I think that’s probably the right call. For many people, lung cancer is highly preventable — just don’t smoke — but it would be weird not to call lung cancer a disease.

The decision wasn’t without debate, though. In fact, the AMA’s Council on Science and Public Health actually recommended against calling obesity a disease. The main issue revolves around using body mass index, or BMI, as a measure for obesity. A 5’11” man who weighs 215 pounds is technically obese, but he may be fairly healthy and probably doesn’t need to be treated aggressively. There was also a worry that calling obesity a disease might let people off the hook in trying to prevent it in the first place.

Ultimately, the AMA’s House of Delegates ignored the council’s recommendation, voting in favor of a resolution to recognize obesity as a disease.

Great news for these companies
In the past, there’s been a distinct lack of interest in treating obesity. Doctors felt that it was mostly an aesthetic issue, so drugs to treat obesity had to be very safe. The severity of the disease is always a consideration in the acceptability of how severe side effects can be.

More recently, it’s become clear that obesity is a risk factor for other issues including type 2 diabetes and high blood pressure, making prevention and treatment a higher priority.

Abbott Laboratories (NYSE:ABT)

Unfortunately, having Wyeth’s Fen-Phen and Abbott Laboratories (NYSE:ABT)‘s Meridia pulled off the market because of side effect issues made many doctors wary of treatments. VIVUS, Inc. (NASDAQ:VVUS) got off to a very slow start, selling just $4.1 million of its obesity drug Qsymia in the first quarter, its second full quarter on the market.

The AMA’s decision should shed light on the issue, stressing treatment. But I continue to think it’s going to take time before doctors have enough experience prescribing Qsymia and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai’s Belviq that they’re prescribing them to a majority of their obese patients. Clinical trial data is nice, but there’s no substitute for real-life experience on a few select patients.

Perhaps more importantly, the AMA’s decision could affect reimbursement for the drugs. VIVUS, Inc. (NASDAQ:VVUS) and Eisai are slowly gaining coverage from private insurersm, and an endorsement by the AMA certainly won’t hurt their efforts. VIVUS, Inc. (NASDAQ:VVUS) is shooting for 50% coverage of people covered by private insurance by the end of the year  The AMA’s endorsement may also affect government coverage. A bill was recently introduced into Congress that would provide coverage of obesity drugs by Medicare.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) , the third player whose obesity drug could be approved next year, might be hitting the market at the perfect time, just as all the kinks are worked out. And if its drug Contrave is approved, it’ll be the only one to have shown that it doesn’t cause cardiovascular problems.

The article It’s Official: Obesity Is a Disease originally appeared on Fool.com.

Fool contributor Brian Orelli plans to go for a run after finishing this article. He has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!